TY - JOUR
T1 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
AU - Disis, Mary L.
AU - Adams, Sarah F.
AU - Bajpai, Jyoti
AU - Butler, Marcus O.
AU - Curiel, Tyler
AU - Dodt, Shelley A.
AU - Doherty, Laura
AU - Emens, Leisha A.
AU - Friedman, Claire F.
AU - Gatti-Mays, Margaret
AU - Geller, Melissa A.
AU - Jazaeri, Amir
AU - John, Veena S.
AU - Kurnit, Katherine C.
AU - Liao, John B.
AU - Mahdi, Hader
AU - Mills, Anne
AU - Zsiros, Emese
AU - Odunsi, Kunle
N1 - Publisher Copyright:
© 2023 BioMed Central Ltd.. All rights reserved.
PY - 2023/6/9
Y1 - 2023/6/9
N2 - Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer.
AB - Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer.
KW - Clinical Trials as Topic
KW - Genital Neoplasms, Female
KW - Guidelines as Topic
UR - http://www.scopus.com/inward/record.url?scp=85162967876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162967876&partnerID=8YFLogxK
U2 - 10.1136/jitc-2022-006624
DO - 10.1136/jitc-2022-006624
M3 - Article
C2 - 37295818
AN - SCOPUS:85162967876
SN - 2051-1426
VL - 11
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 6
M1 - e006624
ER -